-
Dean Gesme, MD
@mnoncology wrote a summary of interesting research presented@ASCO#GI20 for@OBRtweets. We're excited that the NETest got recognized as a diagnostic tool in#NeuroendocrineCancer!#LiquidBiopsy#LetsTalkAboutNETs http://obroncology.com/blog/deans-digest-asco-gi-2020 … -
Atualização dos dados do BEACON trial na ASCO GI mantendo ganho de SG e com qualidade de vida! Doublet como standard no tratamento p/pts CCRm BRAFm V600E pós falha a 1a linha. Pena que custo ainda exorbitante + vale mais uma vez a discussão de valor na oncologia!
#GI20 pic.twitter.com/LXtru331x3
-
In the cohort of patients that received lenvatinib in the frontline setting, the ORR was 14.0% versus 4.0% in those that received therapy in the second- to fourth-line settings. https://www.targetedonc.com/news/lenvatinib-appears-effective-in-reallife-retrospective-analysis-of-advanced-hcc …
#GI20#hcc -
On
#WorldCancerDay
, we recognize pharmacists who are advancing the treatment of cancer. Assistant Professor Ashley Glode, PharmD, recently presented a poster at the #GI20 showing that less chemotherapy may have more benefit in rectal cancer.#TuesdayTrends http://bit.ly/2SarjJ4 -
Here we are ! Updates from
#gi20 are now ready! Videos released and downloadable slides available on our website. Please enjoy reading and watching!!#oncology#MedEdhttps://giconnect.info/update-from-asco-gi-2020/ … -
thank you! I noticed a lot of the "streaming questions" at ASCO
#GI20 were about eligibilty (e.g. HPV+ or HIV+ pts) and at ASCO GI19 I realized that the trials having problems with accrual had no NCT number... only NRG or SWOG numbers. https://twitter.com/realbowtiedoc/status/1224476775134134273 … -
Dr. Lenz “The incredible complete response rates & overall response rates seen are never seen with chemotherapy, & it’s very well tolerated, so if I have a choice, I would start with nivolumab-ipilimumab in 1st-line
#MSI -H...”#CRCSM from ASCO#GI20 https://www.mdedge.com/hematology-oncology/article/216373/gastroenterology/dual-immunotherapy-goes-distance-msi-h … -
This combination resulted in an overall response rate of 81% in patients with RAS/BRAF-wildtype metastatic colorectal cancer. https://www.targetedonc.com/conference/ascogi-2020/avelumab-added-to-standard-regimen-for-crc-achieves-high-response-rate-but-misses-pfs-end-point …
#coloncancer#Gi20 -
Eyal Meiri, MD, on Pembrolizumab in Colorectal Cancer: Results From the TAPUR Study https://www.ascopost.com/videos/2020-gastrointestinal-cancers-symposium/eyal-meiri-on-pembrolizumab-in-colorectal-cancer/ …
#crcsm#oncology#cancer#GI20 pic.twitter.com/Y8iWk6GYdL
-
"Meetings like
#GI20 serve as an important reminder of the brilliant and compassionate people around the world who are working every day to improve outcomes for patients facing GI cancers, like#pancreaticcancer."@LynnMatrisian@PanCANhttps://twitter.com/PanCAN/status/1223009245580472322 … -
"Hit the wall" last night... with some patient advocacy burnout. LOVED going to ASCO
#GI20... but need to get the damn dishes washed! My motto today: try to do the least I can do. Feel better already! -
There may be a gut microbe connection to the increased incidence of CRC in younger patients.
#GI20 http://ms.spr.ly/6011TZMXZ -
A great start for the year 2020! Two abstracts on
#rwe at#GI20 ! Thanks Drs@winsoncheung and Patricia Tang!pic.twitter.com/UmXXF5jdCQ
-
When you’re a patient of Heinz-Josef Lenz, you have to be an informed patient so you can properly geek out over his research: Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Metastatic CRC
#GI20 https://www.ascopost.com/videos/2020-gastrointestinal-cancers-symposium/heinz-josef-lenz-on-nivolumab-plus-low-dose-ipilimumab-as-first-line-therapy-for-metastatic-crc/?fbclid=IwAR3gtTcK9AlJJwWhvm0skcANbd1zqEDN_vSx_aDLIaMBhEgyxUErpHCNmhY … -
And we present data at
#GI20 that says screening colonoscopies in 100,000 people < 50y saves 7 lives, & we feel OK to argue that the # of lives lost when 100,000 people undergo colonoscopies, is 7 (even though the data is from older adults).. but don't want to find "solutions" -
Last week at
#GI20, we presented real-world patterns of care among metastatic pancreatic cancer patients and discussed how we can better serve the#pancreaticcancer, GI and pancreatic#NETs communities. Thanks,@ASCO, for another impactful meeting.pic.twitter.com/qo2AjAner2
-
In the single-arm phase II AVETUX study, the overall response rate to the regimen was 81%, but the 12-month rate of PFS was only 40%,1 which missed the target of 57%
#crcsm#GI20 http://ow.ly/b6KL50y5Qyn -
As a pt advocate, I interacted with many speakers. I felt really listened to & very welcomed. Almost everyone I talked to was interested, willing & eager to discuss many aspects of the pt experience. Pts want to engage with docs & be a team to advance their care.
#GI20 7/9 pic.twitter.com/lumMM4nrqw
Prikaži ovu nit -
The survivorship talk was excellent and addressed many imp pt issues, but still a study conceived and delivered by non-patients. This model is great, but can pts add value?
#GI20 6/9 pic.twitter.com/7nYUB4OFDv
Prikaži ovu nit -
Pt experience seemed to be this abstract thing that was guessed about, even though the size of mets in their organs, bacteria in their guts, CtDNA in their blood was measured very accurately & p-values assigned with great care.
#GI20 5/9 pic.twitter.com/jByNcXRlDn
Prikaži ovu nit
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.